• Cellenkos, Inc. ("Cellenkos"), a 22.74% associate of the Group, obtained approval from U.S. Food and Drug Administration ("FDA") to carry out Phase I clinical trial of product CK0802 for treatment of COVID-19 associated acute respiratory distress syndrome

  • Teamed up with Hong Kong Baptist University to conduct cell therapy research
  • Cellenkos obtained approval from U.S. FDA to carry out phase I clinical trial of product CK0801 for treatment of bone marrow failure syndrome and Guillain-Barré syndrome

  • Entered into the cells and tissues storage business and the genetic testing business, laying out strategies for entire biomedical value chain from cells and tissues storage to clinical applications
  • Cellenkos registered its manufacturing facility as good manufacturing practice ("GMP") compliant with U.S. FDA for manufacturing cord blood-derived regulatory T-cells
  • Acquired 50.0% equity interests in ASA Asset Management Co., Ltd., Japan
  • Successfully completed the disposal of the Group’s entire 65.4% equity interest in Global Cord Blood Corporation ("GCBC")
  • Voluntary delisting of the Taiwan depositary receipts on the Taiwan Stock Exchange

  • Entered into the precision medicine business and established cooperations with the University of Texas at MD Anderson Cancer Center and Hope Health Center in the U.S., respectively
  • Beijing Sunbow Obstetrics & Gynecology Hospital commenced operation

  • Acquired the remaining equity interest in GM Hospital Group Limited to consolidate shareholdings in hospital management business

  • New cord blood storage facilities in Guangdong Province and Zhejiang Province opened in the first half of fiscal year 2015

  • Qinghe Hospital located in Beijing Haidian District started its trial run

  • The medical devices segment established a new distribution business for imported high-end overseas medical devices

  • Became the first healthcare enterprise from Mainland China to list its depositary receipts on the Taiwan Stock Exchange
  • Acquired Shanghai East International Medical Center to enter into premium healthcare services martet
  • GCBC secured an exclusive license to operate cord blood storage business in Zhejiang Province

  • Changed its name to "Golden Meditech Holdings Limited" to better reflect the Group's integrated business model, diversified revenue streams and depth exposure in Mainland China's healthcare industry
  • Launched Mainland China's first third-party medical insurance administration, GM-Medicare Management (China) Company Limited, as a joint venture with two leading US-based health maintenance organisations

  • New cord blood storage facility, then the largest cord blood storage facility in the world in terms of capacity and daily processing volume, commenced operation in Beijing
  • Transferred listing from the GEM ("GEM") onto the Main Board of The Stock Exchange of Hong Kong Limited (SEHK: 801)
  • Entered into the hospital management business
  • GCBC (NYSE:CO) successfully listed on the New York Stock Exchange

  • New cord blood storage facilities in Guangdong Province commenced operation

  • Expansion of cord blood storage business into Guangdong Province

  • Strategic investment in the first cord blood bank in Mainland China and commencement of cord blood storage business in Beijing

  • Medical devices production facility in Beijing commenced production

  • Listed on the GEM of the Stock Exchange of Hong Kong Limited (SEHK: 8180)

Back to top